Dear E,

Will you be at the J.P. Morgan Healthcare Conference next month? If so, please join us for the FierceBiotech Executive Breakfast & Panel Discussions on January 14th at the Fairmont Hotel in San Francisco. This year's event will feature a full breakfast buffet, two panel discussions, coffee break, and an Ask the Experts Closing Reception.

During Panel One, Strategic Considerations for the Commercialization of Cell and Gene Therapies, we will speak to key leaders and discuss the challenges to commercializing cell-based and gene therapies, as well as explore how drugmakers are leveraging emerging technologies to meet production requirements, maximize efficiency, and track patients’ progress for performance-based payment deals.

Speakers include:

• Dr. Mitchell Finer / Chief Scientific Officer / ElevateBio
• David J. Lennon, Ph.D. / President / AveXis, a Novartis Company
• Paul Levesque / Global President of Pfizer Rare Disease / Pfizer
• Opening Remarks: Keiko Oishi / President and COO / CMIC
• Alberto Santagostino / Head of Cell and Gene Technologies / Lonza
• Closing Remarks: Stephen J. Ubl / President and Chief Executive Officer / PhRMA
  

Panel Two, The Promise of AI: Can Artificial Intelligence and Machine Learning Really Transform R&D?, will discuss how drug discovery is one area where AI systems can revolutionize the process of R&D. By applying these tools to patient data, from genomics to electronic health records, researchers can gain deeper insights into the populations they’re ultimately trying to treat.

Speakers include:

• Chris Gibson / Co-Founder and CEO / Recursion Pharmaceuticals
• Kevin Julian / Senior Managing Director, Life Sciences / Accenture
• Daphne Koller / CEO and Founder / Insitro
• Christopher McKenna / Global Head of Professional Services & Consulting / Clarivate Analytics
• Melanie Nallicheri / Life Sciences Executive, Former Chief Business Officer and Head / Biopharma, Foundation Medicine; Former SVP, Corporate Strategy and Business Development / McKesson
• Alex Zhavoronkov, PhD / Founder and CEO / Insilico Medicine

Seats are limited and expected to sell out. Early Bird Rates end next Friday, December 13th - click here to register and reserve your spot at the event.

I look forward to seeing you in San Francisco.

Best,

Rebecca Willumson
Publisher
FierceBiotech & FiercePharma